FCGR3A and neoplasm: In the case of bispecific antibodies, TIGIT inhibition alone has no effect on NK cell-mediated cell killing, and CD16 activation slightly increases cytotoxicity; the combination of both Fabs in one molecule, even without tumor targeting moiety, further increases the activating potential of the antibody.